2026-08-29T14:55:52Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/226422025-05-05T11:10:40Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16987col_20.500.12105_16988

00925njm 22002777a 4500 dc Caniglia, Ellen C author Phillips, Andrew author Porter, Kholoud author Sabin, Caroline A author Winston, Alan author Logan, Roger author Gill, John author Vandenhende, Marie-Anne author Barger, Diana author Lodi, Sara author Moreno, Santiago author Ramon Arribas, Jose author Pacheco, Antonio author Cardoso, Sandra W author Chrysos, George author Gogos, Charalabos author Abgrall, Sophie author Costagliola, Dominique author Meyer, Laurence author Seng, Remonie author van Sighem, Ard author Reiss, Peter author Muga, Roberto author Pérez-Hoyos, Santiago author Braun, Dominique author Hauser, Christoph author Barrufet, Pilar author Leyes Garcia, Maria author Tate, Janet author Justice, Amy author Hernán, Miguel A author HIV-CAUSAL Collaboration author 2018-01-01 Background: The differential effects of commonly prescribed combined antiretroviral therapy (cART) regimens on AIDS-defining neurological conditions (neuroAIDS) remain unknown. Setting: Prospective cohort studies of HIV-positive individuals from Europe and the Americas included in the HIV-CAUSAL Collaboration. Methods: Individuals who initiated a first-line cART regimen in 2004 or later containing a nucleoside reverse transcriptase inhibitor backbone and either atazanavir, lopinavir, darunavir, or efavirenz were followed from cART initiation until death, lost to follow-up, pregnancy, the cohort-specific administrative end of follow-up, or the event of interest, whichever occurred earliest. We evaluated 4 neuroAIDS conditions: HIV dementia and the opportunistic infections toxoplasmosis, cryptococcal meningitis, and progressive multifocal leukoencephalopathy. For each outcome, we estimated hazard ratios for atazanavir, lopinavir, and darunavir compared with efavirenz via a pooled logistic model. Our models were adjusted for baseline demographic and clinical characteristics. Results: Twenty six thousand one hundred seventy-two individuals initiated efavirenz, 5858 initiated atazanavir, 8479 initiated lopinavir, and 4799 initiated darunavir. Compared with efavirenz, the adjusted HIV dementia hazard ratios (95% confidence intervals) were 1.72 (1.00 to 2.96) for atazanavir, 2.21 (1.38 to 3.54) for lopinavir, and 1.41 (0.61 to 3.24) for darunavir. The respective hazard ratios (95% confidence intervals) for the combined end point were 1.18 (0.74 to 1.88) for atazanavir, 1.61 (1.14 to 2.27) for lopinavir, and 1.36 (0.74 to 2.48) for darunavir. The results varied in subsets defined by calendar year, nucleoside reverse transcriptase inhibitor backbone, and age. Conclusion: Our results are consistent with an increased risk of neuroAIDS after initiating lopinavir compared with efavirenz, but temporal changes in prescribing trends and confounding by indication could explain our findings. Caniglia Ellen C., Phillips Andrew, Porter Kholoud, Sabin Caroline A., Winston Alan, Logan Roger, et al. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. JAIDS. 2018 Jan 01;77(1):102-109. 10.1097/QAI.0000000000001562 1077-9450 1525-4135 JAIDS-Journal of Acquired Immune Deficiency Syndromes http://hdl.handle.net/20.500.13003/9463 28991888 L619870153 2-s2.0-85038377563 https://hdl.handle.net/20.500.12105/22642 429107900018 HIV HIV dementia Antiretroviral therapy NeuroAIDS Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions